-+ 0.00%
-+ 0.00%
-+ 0.00%

AGOMAB ANNOUNCES FIRST PATIENT DOSED IN GLOBAL NOV-ERA PHASE 2B STUDY OF ONTUNISERTIB IN FIBROSTENOSING CROHN'S DISEASE

Reuters·10/13/2026 20:07:24